Recommendations on treatments, risk groups, infection control measures, and vaccinations for COVID-19 have been updated to take new evidence into account

COVID-19 virus

NICE and Public Health England (PHE) have published updated versions of key guidelines on the management of COVID-19, which provide new recommendations on treatments, risk groups, infection control measures, and vaccinations for COVID-19.

NICE Guideline 191

On 2 September 2021, NICE updated NICE Guideline 191, COVID-19 rapid guideline: managing COVID-19, which covers the management of COVID-19 in children, young people, and adults in all care settings. The guideline aims to provide a single source for existing guidance and new recommendations on the management of COVID-19, and is continually updated as new evidence emerges. In this update, recommendations have been added on non-invasive respiratory support and doxycycline, and existing recommendations on heparins have been updated.

PHE guidance

In addition, PHE has revised COVID-19: the green book, chapter 14a and COVID-19: infection prevention and control (IPC).

COVID-19: the green book, chapter 14a, which provides COVID-19 vaccination information for public health professionals, has been updated to include:

  • information on third dose primary vaccination for severely immunosuppressed patients
  • revised risk groups for children
  • polyethylene glycol allergy advice
  • background information
  • regulatory information.

In the 2 September 2021 update to COVID-19: infection prevention and control (IPC), which provides guidance on infection prevention and control for health and social care providers involved in receiving, assessing, and caring for patients with possible or confirmed COVID-19, the standard isolation period advised for contacts of cases within inpatient settings has been changed back from 10 to 14 days, in line with current healthcare guidance.